Slingshot members are tracking this event:

Keryx Biopharmaceuticals announced an interruption in the supply of Auryxia (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient (API) to finished

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Keryx expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels, which Keryx anticipates will be during the fourth quarter of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ferric Citrate, Api, Supply, Interruption, Cyclobenzaprine, Hyperphosphatemia